Trial of Maraviroc (UK-427,857) in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of HIV-1 Infected Subjects (MOTIVATE 2)

This study has been completed.
Sponsor:
Collaborator:
Pfizer
Information provided by (Responsible Party):
ViiV Healthcare
ClinicalTrials.gov Identifier:
NCT00098722
First received: December 7, 2004
Last updated: April 16, 2012
Last verified: April 2012
  Purpose

Maraviroc (UK-427,857), a selective and reversible CCR5 coreceptor antagonist, has been shown to be active in vitro against a wide range of clinical isolates (including those resistant to existing classes). In HIV-1 infected patients, maraviroc (UK-427,857) given as monotherapy for 10 days reduced HIV-1 viral load by up to 1.6 log, consistent with currently available agents. Safety and toleration have been studied in over 400 subjects for up to 28 days at 300 mg twice daily. No significant effects were seen on the QTc interval. The purpose of this study is to evaluate the antiretroviral activity of maraviroc (UK-427,857) in HIV infected, treatment experienced patients who are failing their current antiretroviral regimen and infected with R5-tropic virus exclusively. This study will involve more than 100 centers in Europe and Australia to achieve a total randomized subject population of 500 subjects. Patients will be randomly (2:2:1) assigned to one of three groups: Optimized Background Therapy [OBT (3-6 drugs based on treatment history and resistance testing)] + maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone. The study will enroll over approximately a 9 month period with 48 weeks of treatment. This may be extended for an additional year depending on the results at 48 weeks. Physical examinations will be performed at study entry, weeks 4, 8, 12, 16, 20, 24, 32, 40 and 48. Blood samples will also be taken at study entry, weeks 2, 4, 8, 12, 16, 20, 24, 32, 40 and 48. Additionally, blood samples will be drawn twice, at least 30 minutes apart, at weeks 2 and 24 for maraviroc (UK-427,857) pharmacokinetic analysis. As part of this clinical study a blood sample will also be taken for non-anonymized pharmacogenetic analysis. Patients will undergo a 12-lead electrocardiogram at study entry, weeks 24 and 48.


Condition Intervention Phase
HIV Infections
Drug: Maraviroc (UK-427,857)
Drug: optimized background therapy
Phase 2
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of a Novel CCR5 Antagonist, UK-427,857, in Combination With Optimized Background Therapy Versus Optimized Background Therapy Alone for the Treatment of Antiretroviral-Experienced HIV-1 Infected Subjects

Resource links provided by NLM:


Further study details as provided by ViiV Healthcare:

Primary Outcome Measures:
  • Log 10-transformed Human Immunodeficiency Virus Ribonucleic Acid (HIV-1 RNA) Levels at Baseline [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and immediately pre-dose.

  • Change From Baseline in Log 10-transformed HIV-1 RNA Levels at Week 24 [ Time Frame: Baseline and Week 24 ] [ Designated as safety issue: No ]
    Change from baseline in log 10-transformed plasma viral load (HIV-1 RNA) levels (log10 copies/mL). Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and immediately pre-dose.

  • Change From Baseline in Log 10-transformed HIV-1 RNA Levels at Week 48 [ Time Frame: Baseline and Week 48 ] [ Designated as safety issue: No ]
    Change from baseline in log 10-transformed plasma viral load (HIV-1 RNA) levels (log10 copies/mL). Baseline value calculated as average of pre-dose measurements collected at screening, randomization, and immediately pre-dose.


Secondary Outcome Measures:
  • Percentage of Participants With HIV-1 RNA Levels Less Than 400 Copies/mL [ Time Frame: Week 24 and 48 ] [ Designated as safety issue: No ]
  • Percentage of Participants With HIV-1 RNA Levels Less Than 400 Copies/ml or With at Least 0.5 log10 Decrease From Baseline [ Time Frame: Week 24 and 48 ] [ Designated as safety issue: No ]
  • Percentage of Participants With HIV-1 RNA Levels Less Than 400 Copies/ml or With at Least 1.0 log10 Decrease From Baseline [ Time Frame: Week 24 and 48 ] [ Designated as safety issue: No ]
  • Percentage of Participants With HIV-1 RNA Levels Less Than 50 Copies/mL [ Time Frame: Week 24 and 48 ] [ Designated as safety issue: No ]
  • Cluster of Differentiation 4 (CD4) and Cluster of Differentiation 8 (CD8) Cell Count at Baseline [ Time Frame: Baseline ] [ Designated as safety issue: No ]
    Baseline value calculated as average of pre-dose measurements collected at screening and immediately pre-dose.

  • Change From Baseline in CD4 Cell Count at Week 24 and 48 [ Time Frame: Week 24 and 48 ] [ Designated as safety issue: No ]
    Change from baseline in CD4 cell count measured as cells/µL. Baseline value calculated as average of pre-dose measurements collected at screening and immediately pre-dose.

  • Change From Baseline in CD8 Cell Count at Week 24 and 48 [ Time Frame: Week 24 and 48 ] [ Designated as safety issue: No ]
    Change from baseline in CD8 cell count measured as cells/µL. Baseline value calculated as average of pre-dose measurements collected at screening and immediately pre-dose.

  • Time to Virological Failure [ Time Frame: Week 48 ] [ Designated as safety issue: No ]
    Time to virologic failure based on observed HIV-1 RNA levels and failure events (death;permanent discontinuation of drug;lost to follow-up[LTFU];new anti-retroviral drug added [except background drug change to drug of same class];or on open label for early non-response or rebound). Failure:at Time 0 if level not <400 copies/mL (2 consecutive visits) before events or last available visit;at time of earliest event if level <400 copies/mL (2 consecutive visits);failure if level >=400 copies/mL (2 consecutive visits) or 1 visit >=400 copies/mL followed by permanent discontinuation of drug or LTFU.

  • Time-Averaged Difference (TAD) From Baseline in log10 Transformed HIV-1 RNA Levels [ Time Frame: Baseline to Week 24 and Week 48 ] [ Designated as safety issue: No ]
    TAD from baseline was calculated as area under the curve of HIV-1 RNA load (log10 copies/mL) divided by time period minus baseline HIV-1 RNA load (log10 copies/mL). Baseline value calculated as the average of pre-dose measurements collected at screening, randomization, and immediately pre-dose.

  • Number of Participants With Genotypic Susceptibility Score (GSS) and Phenotypic Susceptibility Score (PSS) at Screening [ Time Frame: Screening ] [ Designated as safety issue: No ]
    Number of participants with GSS and PSS were used as surrogates for genotype and phenotype. Genotypic and phenotypic resistance to protease inhibitors(PIs), nucleoside reverse transcriptase inhibitors(NRTIs) and non-nucleoside reverse transcriptase inhibitors(NNRTIs) were evaluated at screening (not at baseline), by Monogram Biosciences PhenoSense genotyping (GT) assay. Score was determined for each drug in OBT, giving 1:drug 'sensitive'/'susceptible' and 0:'resistant'. GSS and PSS score range:0 to >3. Genotypic enfuvirtide value was used for PSS, no phenotypic enfuvirtide was recorded.

  • Number of Participants With Change in GSS and PSS From Screening at the Time of Treatment Failure Through Week 24 [ Time Frame: Screening and time of failure through Week 24 ] [ Designated as safety issue: No ]
    Number of participants with GSS and PSS were used as surrogates for genotype and phenotype. Genotypic and phenotypic resistance to PIs, NRTIs, NNRTIs were evaluated at screening and time of treatment failure analyzed through Week 24 visit, by Monogram Biosciences PhenoSense GT assay. Score was determined for each drug in OBT, giving 1:drug 'sensitive'/'susceptible' and 0:'resistant'. GSS and PSS score range:0 to >3. Genotypic enfuvirtide value was used for PSS, no phenotypic enfuvirtide was recorded.

  • Number of Participants With Change in GSS and PSS From Screening at the Time of Treatment Failure Through Week 48 [ Time Frame: Screening and time of failure through Week 48 ] [ Designated as safety issue: No ]
    Number of participants with GSS and PSS were used as surrogates for genotype and phenotype. Genotypic and phenotypic resistance to PIs, NRTIs, NNRTIs were evaluated at screening and time of treatment failure analyzed through Week 48 visit, by Monogram Biosciences PhenoSense GT assay. Score was determined for each drug in OBT, giving 1:drug 'sensitive'/'susceptible' and 0:'resistant'. GSS and PSS score range:0 to >3. Genotypic enfuvirtide value was used for PSS, no phenotypic enfuvirtide was recorded.

  • Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 24 [ Time Frame: Baseline and time of failure through Week 24 ] [ Designated as safety issue: No ]
    Number of participants per tropism status (C-X-C chemokine receptor 5 {CCR5} [R5], C-X-C chemokine receptor type 4 {CXCR4} [X4], Dual/Mixed [DM], or Non-reportable/Non-phenotypable [NR/NP]) at baseline and time of treatment failure analyzed through week 24 visit. Treatment failure defined as discontinuation due to insufficient clinical response. HIV-1 RNA viral load <500 copies/ml categorized as below lower limit of quantification (BLQ). The assessment for time of treatment failure was defined as the last on treatment assessment.

  • Number of Participants Per Tropism Status at Baseline and at the Time of Treatment Failure Through Week 48 [ Time Frame: Baseline and time of failure through Week 48 ] [ Designated as safety issue: No ]
    Number of participants per tropism status R5, X4, DM, or NR/NP at baseline and time of failure analyzed through week 48 visit. Treatment failure defined as discontinuation due to insufficient clinical response. HIV-1 RNA viral load <500 copies/ml categorized as BLQ. The assessment for time of treatment failure was defined as the last on treatment assessment.

  • Change From Baseline in Viral Load at Week 24 and Week 48 by Overall Susceptibility Score (OSS) at Screening [ Time Frame: Baseline, Week 24 and Week 48 ] [ Designated as safety issue: No ]
    Association between baseline resistance and virological response was assessed as change in viral load by OSS at screening. OSS categorized as 0, 1, 2, >3 (maximum value of 6) and calculated as the sum of the net assessment of in-vitro phenotypic and genotypic susceptibility using a binary scoring system (0= resistant, 1= sensitive or susceptible) for each antiretroviral agent in OBT. Higher scores indicate greater susceptibility. Baseline value is the average of the values from screening, randomization and immediately pre-dose.


Enrollment: 474
Study Start Date: December 2004
Study Completion Date: April 2011
Primary Completion Date: April 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: 1 Drug: Maraviroc (UK-427,857)
maraviroc (UK-427,857) 150 mg taken once daily, OBT + maraviroc (UK-427,857) 150 mg taken twice daily, or OBT alone.
Drug: optimized background therapy
[OBT (3-6 drugs based on treatment history and resistance testing)]
Other Name: Selzentry
Placebo Comparator: 2 Drug: Maraviroc (UK-427,857)
maraviroc (UK-427,857) 150 mg taken twice daily
Other Name: Selzentry
Drug: optimized background therapy
[OBT (3-6 drugs based on treatment history and resistance testing)]
Experimental: 3 Drug: optimized background therapy
[OBT (3-6 drugs based on treatment history and resistance testing)]

  Eligibility

Ages Eligible for Study:   16 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Men or women at least 16 yers of age (or minimum age as determined by local regulatory authorities)
  • HIV-1 RNA viral load of greater than or equal to 5,000 copies/mL
  • Stable pre-study antiretroviral regimen, or on no antiretroviral agents, for at least 4 weeks
  • Documented genotypic or phenotypic resistance to three of the four antiretroviral drug classes, OR, Antiretroviral-class experience greater than or equal to 6 months (sequential or cumulative) with at least three of the following: One nucleoside or nucleotide reverse transcriptase inhibitor, one non-nucleoside reverse transcriptase inhibitor, two protease inhibitors (excluding low-dose ritonavir) and/or enfuvirtide
  • Be willing to remain on randomized treatment without any changes or additions to the OBT regimen, except for toxicity management or upon meeting criteria for treatment failure
  • A negative urine pregnancy test at the baseline visit for Women of Child Bearing Potential (WOCBP)
  • Effective barrier contraception for WOCBP and males

Exclusion Criteria:

  • Patients requiring treatment with more than 6 antiretroviral agents (excluding low-dose ritonavir)
  • Prior treatment with maraviroc (UK-427,857) or another experimental HIV entry inhibitor for more than 14 days
  • Suspected or documented active, untreated HIV-1 related opportunistic infection (OI) or other condition requiring acute therapy
  • Treatment for an active opportunistic infection, or unexplained temperature >38.5 degrees Celsius for 7 consecutive days
  • Active alcohol or substance abuse sufficient, in the Investigator's judgment, to prevent adherence to study medication and/or follow up
  • Lactating women, or planned pregnancy during the trial period
  • Significant renal insufficiency
  • Initiating therapy with a potentially myelosuppressive, neurotoxic, hepatotoxic and/or cytotoxic agent within 60 days prior to randomization or the expected need for such therapy during the study period
  • Documented or suspected acute hepatitis or pancreatitis within 30 days prior to randomization
  • Significantly elevated liver enzymes or cirrhosis
  • Significant neutropenia, anemia or thrombocytopenia
  • Malabsorption or an inability to tolerate oral medications
  • Certain medications
  • Malignancy requiring parenteral chemotherapy that must be continued for the duration of the trial
  • X4- or dual/mixed-tropic virus or repeated assay failure
  • Any other clinical condition that, in the Investigator's judgement, would potentially compromise study compliance or the ability to evaluate safety/efficacy
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00098722

  Hide Study Locations
Locations
United States, Alabama
Pfizer Investigational Site
Hobson City, Alabama, United States, 36201
United States, California
Pfizer Investigational Site
Garden Grove, California, United States, 92845
Pfizer Investigational Site
Los Angeles, California, United States, 90036
Pfizer Investigational Site
Oakland, California, United States, 94609-3480
Pfizer Investigational Site
Palm Springs, California, United States, 92262
Pfizer Investigational Site
Tarzana, California, United States, 91356
United States, Connecticut
Pfizer Investigational Site
Norwalk, Connecticut, United States, 06851
Pfizer Investigational Site
Southport, Connecticut, United States, 06490
Pfizer Investigational Site
Stratford, Connecticut, United States, 06614
United States, District of Columbia
Pfizer Investigational Site
Washington, District of Columbia, United States, 20010-2976
Pfizer Investigational Site
Washington, District of Columbia, United States, 20007
United States, Florida
Pfizer Investigational Site
Clearwater, Florida, United States, 33765
Pfizer Investigational Site
Hollywood, Florida, United States, 33021-6327
Pfizer Investigational Site
Miami, Florida, United States, 33137
Pfizer Investigational Site
Miami, Florida, United States, 33155
Pfizer Investigational Site
Miami, Florida, United States, 33145
Pfizer Investigational Site
Miami Beach, Florida, United States, 33139
Pfizer Investigational Site
Pensacola, Florida, United States, 32504
Pfizer Investigational Site
Safety Harbor, Florida, United States, 34695
Pfizer Investigational Site
St. Petersburg, Florida, United States, 33713
Pfizer Investigational Site
Tampa, Florida, United States, 33614
Pfizer Investigational Site
Tampa, Florida, United States, 33611
United States, Georgia
Pfizer Investigational Site
Atlanta, Georgia, United States, 30318-2513
Pfizer Investigational Site
Atlanta, Georgia, United States, 30339-3915
Pfizer Investigational Site
Atlanta, Georgia, United States, 30309
Pfizer Investigational Site
Jonesboro, Georgia, United States, 30236
United States, Illinois
Pfizer Investigational Site
Chicago, Illinois, United States, 60657
Pfizer Investigational Site
Chicago, Illinois, United States, 60613
Pfizer Investigational Site
Springfield, Illinois, United States, 62702
United States, Louisiana
Pfizer Investigational Site
Metairie, Louisiana, United States, 70006
United States, Maryland
Pfizer Investigational Site
Baltimore, Maryland, United States, 21201
Pfizer Investigational Site
Silver Spring, Maryland, United States, 20910
United States, Michigan
Pfizer Investigational Site
Ann Arbor, Michigan, United States, 48109-0008
Pfizer Investigational Site
Ann Arbor, Michigan, United States, 48109-0352
Pfizer Investigational Site
Detroit, Michigan, United States, 48201
Pfizer Investigational Site
Detroit, Michigan, United States, 48202
United States, Missouri
Pfizer Investigational Site
Kansas City, Missouri, United States, 64106
Pfizer Investigational Site
Saint Louis, Missouri, United States, 63139-2909
United States, New York
Pfizer Investigational Site
Buffalo, New York, United States, 14215
Pfizer Investigational Site
East Meadow, New York, United States, 11554
Pfizer Investigational Site
Elmira, New York, United States, 14905
Pfizer Investigational Site
New York, New York, United States, 10029
Pfizer Investigational Site
New York, New York, United States, 10025
Pfizer Investigational Site
New York, New York, United States, 10011
Pfizer Investigational Site
New York, New York, United States, 10016
United States, North Carolina
Pfizer Investigational Site
Greenville, North Carolina, United States, 27834
United States, Ohio
Pfizer Investigational Site
Akron, Ohio, United States, 44304
Pfizer Investigational Site
Cleveland, Ohio, United States, 44109
United States, Oklahoma
Pfizer Investigational Site
Tulsa, Oklahoma, United States, 74135
United States, Oregon
Pfizer Investigational Site
Portland, Oregon, United States, 97210
Pfizer Investigational Site
Portland, Oregon, United States, 97227
United States, Pennsylvania
Pfizer Investigational Site
West Reading, Pennsylvania, United States, 19611
United States, South Carolina
Pfizer Investigational Site
Charleston, South Carolina, United States, 29403
Pfizer Investigational Site
Charleston, South Carolina, United States, 29425
United States, Texas
Pfizer Investigational Site
Dallas, Texas, United States, 75219
Pfizer Investigational Site
Fort Worth, Texas, United States, 76107
Pfizer Investigational Site
Fort Worth, Texas, United States, 76104
Pfizer Investigational Site
Pasadena, Texas, United States, 77505-4245
United States, Virginia
Pfizer Investigational Site
Danville, Virginia, United States, 24541
Pfizer Investigational Site
Hampton, Virginia, United States, 23666
Pfizer Investigational Site
Lynchburg, Virginia, United States, 24501
Pfizer Investigational Site
Richmond, Virginia, United States, 23298
Australia, New South Wales
Pfizer Investigational Site
Burwood, New South Wales, Australia, 2134
Pfizer Investigational Site
Darlinghurst, New South Wales, Australia, 2010
Pfizer Investigational Site
Surry Hills, New South Wales, Australia, 2010
Pfizer Investigational Site
Sydney, New South Wales, Australia, 2010
Pfizer Investigational Site
Wentworthville, New South Wales, Australia, 2145
Australia, Queensland
Pfizer Investigational Site
Herston, Queensland, Australia, 4029
Pfizer Investigational Site
Miami, Queensland, Australia, 4220
Australia, Victoria
Pfizer Investigational Site
Melbourne, Victoria, Australia, 3004
Pfizer Investigational Site
North Fitzroy, Victoria, Australia, 3068
Pfizer Investigational Site
South Yarra, Victoria, Australia, 3141
Australia
Pfizer Investigational Site
Darlinghurst, Australia, 2010
Belgium
Pfizer Investigational Site
Brussels, Belgium, 1070
Pfizer Investigational Site
Brussels, Belgium, 1000
Pfizer Investigational Site
Brussels, Belgium, 1200
Pfizer Investigational Site
Gent, Belgium, 9000
Pfizer Investigational Site
Liege, Belgium, 4000
Canada, Quebec
Pfizer Investigational Site
Montreal, Quebec, Canada, H2L 2W5
Pfizer Investigational Site
Montreal, Quebec, Canada, H2L 4M1
France
Pfizer Investigational Site
Toulon, Bp1412, France, 83056
Pfizer Investigational Site
Lyon, Cedex 02, France, 69288
Pfizer Investigational Site
Orleans, Cedex 02, France, 45067
Pfizer Investigational Site
Marseille, Cedex 09, France, 13274
Pfizer Investigational Site
Paris, Cedex 10, France, 75475
Pfizer Investigational Site
Paris, Cedex 12, France, 75571
Pfizer Investigational Site
Bobigny, Cedex, France, 93009
Pfizer Investigational Site
Caen, Cedex, France, 14033
Pfizer Investigational Site
Le Kremlin Bicêtre, France, 94270
Pfizer Investigational Site
Montpellier, France, 34295
Pfizer Investigational Site
Nantes, France, 44093
Pfizer Investigational Site
Nice Cedex 3, 06, France, 06202
Pfizer Investigational Site
Paris, France, 75018
Pfizer Investigational Site
Paris, France, 75015
Pfizer Investigational Site
Paris, 75, France, 75020
Germany
Pfizer Investigational Site
Aachen, Germany, 52062
Pfizer Investigational Site
Berlin, Germany, 12157
Pfizer Investigational Site
Bochum, Germany, 44791
Pfizer Investigational Site
Bonn, Germany, 53105
Pfizer Investigational Site
Duesseldorf, Germany, 40225
Pfizer Investigational Site
Erlangen, Germany, 91054
Pfizer Investigational Site
Essen, Germany, 45122
Pfizer Investigational Site
Frankfurt, Germany, 60590
Pfizer Investigational Site
Freiburg, Germany, 79098
Pfizer Investigational Site
Fuerth, Germany, 90762
Pfizer Investigational Site
Hamburg, Germany, 20246
Pfizer Investigational Site
Hamburg, Germany, 20099
Pfizer Investigational Site
Hannover, Germany, 30625
Pfizer Investigational Site
Koeln, Germany, 50924
Pfizer Investigational Site
Mannheim, Germany, 68161
Pfizer Investigational Site
Muenchen, Germany, 80336
Pfizer Investigational Site
Osnabrueck, Germany, 49090
Pfizer Investigational Site
Stuttgart, Germany, 70197
Pfizer Investigational Site
Ulm, Germany, 89081
Italy
Pfizer Investigational Site
Antella (FI), Italy, 50011
Pfizer Investigational Site
Brescia, Italy, 25123
Pfizer Investigational Site
Firenze, Italy, 50193
Pfizer Investigational Site
Genova, Italy, 16132
Pfizer Investigational Site
Milano, Italy, 20100
Pfizer Investigational Site
Modena, Italy, 41100
Pfizer Investigational Site
Monserrato, CA, Italy, 09042
Pfizer Investigational Site
Roma, Italy, 00161
Pfizer Investigational Site
Roma, Italy, 00185
Pfizer Investigational Site
Roma, Italy, 00184
Pfizer Investigational Site
Torino, Italy, 10149
Pfizer Investigational Site
Venezia, Italy, 30170
Netherlands
Pfizer Investigational Site
Amsterdam, Netherlands, 1081 HV
Pfizer Investigational Site
Amsterdam, Netherlands, 1105 AZ
Pfizer Investigational Site
Arnhem, Netherlands, 6815 AD
Pfizer Investigational Site
Rotterdam, Netherlands, 3015 GD
Pfizer Investigational Site
Utrecht, Netherlands, 3584 CX
Poland
Pfizer Investigational Site
Bialystok, Poland, 15-540
Pfizer Investigational Site
Bydgoszcz, Poland, 85-030
Pfizer Investigational Site
Chorzow, Poland, 41-500
Pfizer Investigational Site
Gdansk, Poland, 80-214
Pfizer Investigational Site
Krakow, Poland, 31-531
Pfizer Investigational Site
Szczecin, Poland, 71-455
Pfizer Investigational Site
Warszawa, Poland, 01-201
Spain
Pfizer Investigational Site
Elche, Alicante, Spain, 03202
Pfizer Investigational Site
Badalona, Barcelona, Spain, 08916
Pfizer Investigational Site
Barcelona, Spain, 08036
Pfizer Investigational Site
Barcelona, Spain, 08025
Pfizer Investigational Site
Cordoba, Spain, 14004
Pfizer Investigational Site
Madrid, Spain, 28034
Pfizer Investigational Site
Madrid, Spain, 28006
Pfizer Investigational Site
Madrid, Spain, 28041
Pfizer Investigational Site
Madrid, Spain, 28029
Pfizer Investigational Site
Madrid, Spain, 28046
Pfizer Investigational Site
San Sebastian, Spain, 20014
Pfizer Investigational Site
Sevilla, Spain, 41013
Pfizer Investigational Site
Sevilla, Spain, 41014
Sweden
Pfizer Investigational Site
Venhalsan, Stockholm, Sweden, 118 83
Pfizer Investigational Site
Göteborg, Sweden, 41685
Pfizer Investigational Site
Malmö, Sweden, 214 01
Switzerland
Pfizer Investigational Site
Basel, Switzerland, 4031
Pfizer Investigational Site
Genève, Switzerland
Pfizer Investigational Site
Lausanne, Switzerland, 1011
Pfizer Investigational Site
Lugano, Switzerland, 6900
Pfizer Investigational Site
St. Gallen, Switzerland, 9007
Pfizer Investigational Site
Zürich, Switzerland, 8091
United Kingdom
Pfizer Investigational Site
Leicester, Leics, United Kingdom, LE1 5WW
Pfizer Investigational Site
Edinburgh, Loth, United Kingdom, ED4 2XU
Pfizer Investigational Site
Birmingham, United Kingdom, B9 5SS
Pfizer Investigational Site
Brighton, United Kingdom, BN2 1ES
Pfizer Investigational Site
Edinburgh, United Kingdom, EH4 2XU
Pfizer Investigational Site
London, United Kingdom, W2 1NY
Pfizer Investigational Site
London, United Kingdom, SW17 0QT
Pfizer Investigational Site
London, United Kingdom, SE5 9RS
Pfizer Investigational Site
London, United Kingdom, NW3 2QG
Pfizer Investigational Site
London, United Kingdom, SW10 9TH
Pfizer Investigational Site
Manchester, United Kingdom, M8 5RB
Pfizer Investigational Site
Newcastle Upon Tyre, United Kingdom, NE4 6BE
Sponsors and Collaborators
ViiV Healthcare
Pfizer
Investigators
Study Director: Pfizer CT.gov Call Center Pfizer
  More Information

Additional Information:
No publications provided by ViiV Healthcare

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: ViiV Healthcare
ClinicalTrials.gov Identifier: NCT00098722     History of Changes
Other Study ID Numbers: A4001028
Study First Received: December 7, 2004
Results First Received: April 16, 2012
Last Updated: April 16, 2012
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
HIV Infections
Acquired Immunodeficiency Syndrome
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases
Slow Virus Diseases

ClinicalTrials.gov processed this record on September 22, 2014